RxDoctor Payments Data

Jenny Gober McDaniel

Pediatric Hematology-Oncology · Las Vegas, NVNPI 1922395649

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (58.0%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. 24 manufacturers reported payments, led by Sanofi at 58.5% of the total.

$43,394in general payments, 2019–2025

Across 83 payments — averaging $522.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi$25K
  • Novo Nordisk AS$12K
  • Pfizer$2K
  • Genentech USA, Inc.$2K
  • Novo Nordisk$452
  • Kedrion Biopharma, Inc.$252
  • plus $1K from 18 others
$38,836in research payments, 2019–2025

Across 99 payments — averaging $392.28 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Novo Nordisk AS$39K

What the payments were for

  • Consulting fees$25,16658%
  • Travel & lodging$13,67432%
  • Food & beverage$4,55410%

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few pediatric hematology-oncology providers in Nevadato place this figure against a meaningful peer group, so we don't.

Other pediatric hematology-oncology in Las Vegas

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →